EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Annual Results/Half Year Results
Lonza Publishes Restated Financials for 2020
29-Jun-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA
Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance
Basel, Switzerland, 29 June 2021 - Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza today is providing restated financials to reflect:
The classification of Lonza's Specialty Ingredients (LSI) business as discontinued operations for Half-Year Result 2020 (consistent with Full-Year 2020 Reporting)
Lonza's redesigned business structure
The revised Alternative Performance Measure (APM) policy
In July 2020, Lonza announced the decision to divest the Specialty Ingredients business via a sale process. Consequently, the LSI operations results were reported as discontinued operations for the Full-Year 2020. The consolidated income statement for the six-month-end 30 June 2020 is now restated to present the LSI business as discontinued operations.
On 15 October 2020, as part of Lonza's Investor Update, Lonza announced, the redesign of its business structure, the revision of its Alternative Performance Measure policy and its decision to increase the threshold for non-CORE adjustments to CHF 20 million per event.
As of 1 January 2021, the former Pharma, Biotech & Nutrition (LPBN) segment was split into four divisions - Small Molecules, Biologics, Cell & Gene1 and Capsules & Health Ingredients. The restated financials for 2020 at a divisional level are now provided for sales and CORE EBITDA.
For Lonza Restated Financials 2020, click the following link:
2020 Restated Financials PDF
1 Cell & Gene division includes Cell & Gene Technologies and Bioscience businesses
About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.
Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
Lonza Contact Details
Media / Communications Team media@lonza.com
Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540 dirk.oehlers@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
LONZA GROUP AG 
